Table 4 Cluster analysis of keywords

1

management (11.22, 0.001); bone graft (8.98, 0.005); reconstruction (8.98, 0.005); bone regeneration (7.43, 0.01); allograft (6.78, 0.01); rat (6.2, 0.05); in vitro (5.63, 0.05); impaction bone grafting (5.6, 0.05); augmentation (5.6, 0.05); transport (5.6, 0.05); vascularized fibular graft (5.6, 0.05); children (5.6, 0.05); lumbar hernia (5.6, 0.05); dental implant (5.6, 0.05); bone tissue engineering (4.49, 0.05); periodontal regeneration (4.49, 0.05); calvarial defect (4.49, 0.05); marrow (4.47, 0.05); model (4.47, 0.05); guided tissue regeneration (4.31, 0.05); bone defect (3.91, 0.05)

Management of bone graft

2

bone regeneration (17.05, 1.0E-4); periodontal regeneration (13.4, 0.001); mandibular molar (10.81, 0.005); guided tissue regeneration (8.64, 0.005); freeze dried bone (7.2, 0.01); clinical evaluation (7.2, 0.01); alveolar bone fill (7.2, 0.01); radiography (7.2, 0.01); reconstructive osseous surgery (7.2, 0.01); membranes artificial (7.2, 0.01); intrabony defects (7.2, 0.01); osseous grafting (7.2, 0.01); peri-implantitis (6.67, 0.01)

Dental bone regeneration technology

3

rat (15.58, 1.0E-4); demineralized bone (14.88, 0.001); purification (10.55, 0.005); induction (9.9, 0.005); composite (9.9, 0.005); osteogenin (9.9, 0.005); bone freeze-dried (6.26, 0.05); porous hydroxyapatite (6.26, 0.05); inductive protein (6.26, 0.05); rabbit (6.01, 0.05); osteoblast (4.94, 0.05); matrix (4.94, 0.05); osteogenic effect (4.94, 0.05); periradicular surgery (4.94, 0.05); fibrin collagen paste (4.94, 0.05); decalcified bone (4.94, 0.05); hormone (4.94, 0.05); bone/demineralized (4.94, 0.05); nasal tip (4.94, 0.05); local application (4.94, 0.05); periodontitis therapy (4.94, 0.05); male animal (4.94, 0.05); e-ptfe (4.94, 0.05); parietal bone (4.94, 0.05); gentamicin (4.94, 0.05); bioerodible polyorthoester (4.94, 0.05); tetracycline therapeutic use (4.94, 0.05); mesenchymal cell (4.94, 0.05); artificial membranes (4.94, 0.05); skull (4.94, 0.05); gastric pentadecapeptide bpc-157 (4.94, 0.05); doxycycline (4.94, 0.05); family member (4.94, 0.05); skull surgery (4.94, 0.05); periodontal pockets therapy (4.94, 0.05); periodontal diseases therapy (4.94, 0.05); segmental bone defects (4.94, 0.05); calvarial bone defects (4.94, 0.05); experimental (4.94, 0.05); autologous cortical bone (4.94, 0.05); polytetrafluoroethylene (therapeutic use) (4.94, 0.05); octacalcium phosphate (4.94, 0.05); substitute (4.94, 0.05); capacity (4.94, 0.05); intramuscular application (4.94, 0.05); stomach (4.94, 0.05); prostaglandin (4.94, 0.05); male rats (4.94, 0.05); attachment (4.94, 0.05); morphogenetic protein (4.71, 0.05); implantation (4.71, 0.05)

Bone formation in rats with bone defects

4

bone tissue engineering (19.2, 1.0E-4); angiogenesis (14.38, 0.001); guided tissue regeneration (12.29, 0.001); calvarial defect (11.47, 0.001); membranes (10.82, 0.005); osteogenic differentiation (9.57, 0.005); mesenchymal stem cell (6.81, 0.01); in vitro (6.71, 0.01); bone graft (5.71, 0.05); reconstruction (5.71, 0.05); periodontal diseases/therapy (5.71, 0.05); demineralized bone matrix (5.29, 0.05); scaffold (5.07, 0.05); hydroxyapatite/therapeutic use (4.99, 0.05); polycaprolactone (4.78, 0.05); beta tricalcium phosphate (4.78, 0.05); marrow stromal cell (4.78, 0.05); vivo (4.78, 0.05); femoral defect (4.78, 0.05); articular cartilage (4.78, 0.05); vitro (4.78, 0.05); proliferation (4.78, 0.05); bmscs (4.78, 0.05); hydroxyapatite scaffold (4.78, 0.05); mandibular reconstruction (4.78, 0.05); delivery (4.78, 0.05); guided bone regeneration (4.61, 0.05); bone substitutes (4.26, 0.05); periodontal diseases/surgery (4.26, 0.05); barrier (4.26, 0.05); outcome assessment (4.26, 0.05)

Application of bone tissue engineering such as biological scaffolds in vascularization and osteogenic differentiation of bone defects

5

membranes (21.65, 1.0E-4); guided bone regeneration (12.99, 0.001); bioabsorbable (11.02, 0.001); comparison studies (11.02, 0.001); barrier (7.52, 0.01); mandible (6.56, 0.05); grafts bone (6.56, 0.05); periodontal diseases/therapy (5.57, 0.05); implant-associated defect (5.1, 0.05); component (5.1, 0.05); cell binding peptide (5.1, 0.05); oral implants (5.1, 0.05); bone allografts (5.1, 0.05); membranes bioabsorbable (5.1, 0.05); gingival recession/therapy (5.1, 0.05); freeze-dried bone (5.1, 0.05); defect (5.1, 0.05); calcium sulfate/therapeutic use (5.1, 0.05); intraosseous defects (5.1, 0.05); gap bone filler (5.1, 0.05); gingival recession/surgery (5.1, 0.05); follow-up studies (5.1, 0.05); gtam (5.1, 0.05); gene expression (5.1, 0.05); controlled (5.1, 0.05); collagen synthesis (5.1, 0.05); laminar bone (5.1, 0.05); dogs (5.1, 0.05); graft healing (5.1, 0.05); implants (5.1, 0.05); osseointegration (5.1, 0.05); acetabulum (5.1, 0.05); osteocalcin (5.1, 0.05); lllt (5.1, 0.05); polytetrafluoroethylene/therapeutic use (5.1, 0.05); alveolar bone loss (5.1, 0.05); resorbable membrane (5.1, 0.05); graft shape (5.1, 0.05); mta (5.1, 0.05); lyodura (5.1, 0.05); finite element analysis (5.1, 0.05); grafts (5, 0.05); bone (4.86, 0.05); guided tissue regeneration (4.02, 0.05); autograft (3.97, 0.05); cancellous bone (3.97, 0.05); clinical trials (3.97, 0.05); artificial (3.97, 0.05); repair (3.76, 0.1)

Membrane-induced bone regeneration

6

hydroxyapatite (14.12, 0.001); osteoconduction (10.26, 0.005); mechanical properties (10.26, 0.005); mechanical property (6.6, 0.05); carbon nanotube (5.12, 0.05); bioactive glas (5.12, 0.05); extrusion free-forming (5.12, 0.05); osteoinduction (5.12, 0.05); arthroplasty (5.12, 0.05); haemocompatibility (5.12, 0.05); repetitive acidic amino acid (5.12, 0.05); composite and powder materials (5.12, 0.05); nanocrystalline hydroxyapatite (5.12, 0.05); bone morphogenic protein 2-related peptide (5.12, 0.05); collagen scaffold (5.12, 0.05); microsphere (5.12, 0.05); nanowire (5.12, 0.05); bone cement (5.12, 0.05); porous tantalum (5.12, 0.05); tetracycline (5.12, 0.05); production process (5.12, 0.05); structure (5.12, 0.05); carbon implants (5.12, 0.05); led phototherapy (5.12, 0.05); nano-hydroxyapatite (5.12, 0.05); bone-implant contact (5.12, 0.05); cement (5.12, 0.05); strength (5.12, 0.05); bioglass (5.12, 0.05); cross linking (5.12, 0.05); nanostructured materials (5.12, 0.05); normal bone (5.12, 0.05); tgf-beta 1 (5.12, 0.05); membrane technique (5.12, 0.05); sintering temperature (5.12, 0.05); silk fibroin (5.12, 0.05); bioactive glass (5.12, 0.05); pattern (5.12, 0.05); slurry-compounding process (5.12, 0.05); drug delivery (5.12, 0.05); new bone formation (5.12, 0.05); hip (5.12, 0.05); weight bearing fracture (5.12, 0.05); early vascularization (5.12, 0.05); lactosorb (5.12, 0.05); tibial fracture (5.03, 0.05); biomaterials (4.01, 0.05); biomaterial (4.01, 0.05)

Nanomaterials induce bone formation

7

extracellular matrix (14.6, 0.001); cartilage (12.45, 0.001); bovine bone (8.91, 0.005); collagen (8.91, 0.005); beta family (8.91, 0.005); mandibular defects (6.3, 0.05); smooth muscle cell (6.3, 0.05); osteogenic protein (6.3, 0.05); camurati engelmann disease (6.3, 0.05); human patients (6.3, 0.05); ectopic induction (6.3, 0.05); transforming growth factor beta 1 (6.3, 0.05); water soluble protein (6.3, 0.05); plate (6.3, 0.05); member (6.3, 0.05); bone induction (6.3, 0.05); colony-forming unit fibroblastic (6.3, 0.05); increased expression (6.3, 0.05); mandibular fracture (6.3, 0.05); cartilage differentiation (6.3, 0.05); hydroxyapatite granules (6.3, 0.05); delivery vehicle (6.3, 0.05); biglycan (6.3, 0.05); osteoinductive implants (6.3, 0.05); fibroblast cells (6.3, 0.05); screw (6.3, 0.05); indian hedgehog (6.3, 0.05); 8 cysteine repeat (6.3, 0.05); new bone (6.3, 0.05); fibronectin (6.3, 0.05)

Extracellular matrix induces cartilage formation and differentiation